ClinicalTrials.gg
RecruitingNCT06241924BAG-OSMOVUpdated Jul 23, 2025

Oscillatory Activity in Basal Ganglia Circuits During Normal and Pathological Movement

An interventional study of High Resolution Electroencephalogram (EEG-HR) and Stereo-electro-encephalography (SEEG) in Parkinson Disease and Epilepsy, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Parkinson Disease by University Hospital, Bordeaux — 4 open to participants now, 4 under way, none of them phase 3. Parkinson Disease · University Hospital, Bordeaux.

Planned enrollment
7th of 12
30 · median 31
Started
2024
the only one that year
No phase
12 of 14
3 open now
Registered
13th of 14
by date

Among the 14 studies in Parkinson Disease by University Hospital, Bordeaux, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2024, is one of 12 with no phase, and was the 13th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

4 of the 14 studies in Parkinson Disease by University Hospital, Bordeaux are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Parkinson Disease by University Hospital, Bordeaux, or all of them as a file.
02

Study summary

The expression of hypokinetic and hyperkinetic motor symptoms is accompanied by pathological synchronous oscillations of neuronal activity in this cortico-subcortical network with a wide frequency range.

The purpose of this research is to study cortico-subcortical oscillations and their synchronization in two pathologies emblematic of hypokinetic (Parkinson's disease) and hyperkinetic (epilepsies) phenomena using a simple motor task and comparing different situations.

Read the detailed description

In order to define the link between the characteristics of the oscillations (frequency, amplitude, phase relation) within this cortico-subcortical network and movement (normal or pathological) in humans, a simple motor task of gripping/pulling a lever has been designed.

The local field potentials (LFPs) will be collected during the same motor task in :

i) patients with Parkinson's disease, using a high-resolution electroencephalogram (EEG) and the PERCEPT(TM) system (Medtronic) equipped with a "sensing" function for deep LFP recordings and in EEG-HR (for high resolution) for cortical recordings

ii) patients with focal drug-resistant epilepsy, during a pre-surgical assessment by stereo-electro-encephalography (SEEG). The SEEG allows the recording of both the cortex and the subcortical regions in a concomitant manner, and a direct correlation can be studied.

03

Conditions studied

  • Parkinson Disease
  • Epilepsy

Keywords

  • Focal seizure
  • Parkinson disease
  • Hyperkinetic seizures
  • Hypokinetic disorders
  • Dyskinesia
  • Networks
  • Basal ganglia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female
  • Between 18 and 75 years of age
  • With Parkinson's disease and already operated with implantation of electrodes in the Subthalamic nucleus connected to a PERCEPT (TM) device.
  • Giving free, informed, written consent signed by the participant and the investigator Or
  • With drug-resistant epilepsy and benefiting from a phase II pre-surgical assessment with intracerebral electrophysiological exploration by stereo-EEG
  • With at least one electrode exploring the basal ganglia or the thalamus.
  • Able to perform the simple motor task
  • Affiliated or beneficiary of a social security scheme;
  • Giving free, informed, written consent signed by the participant and the investigator

Exclusion criteria

Exclusion criteria:

  • Be incapable of giving consent personally
  • Be subject to a legal protection measure or be placed under judicial protection;
  • Being pregnant or breastfeeding
  • Present a serious and/or decompensated somatic or psychiatric illness
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Epilepsy

    Procedure: Stereo-electro-encephalography (SEEG)

  • Experimental
    parkinson disease

    Procedure: High Resolution Electroencephalogram (EEG-HR)

Interventions

  • ProcedureHigh Resolution Electroencephalogram (EEG-HR)

    Local field potentials (LFP) recording using EEG-HR

  • ProcedureStereo-electro-encephalography (SEEG)

    Local field potentials (LFP) recording using sEEG

06

What researchers measure

Primary outcomes

  1. difference in the cortico-subcortical electrophysiological coherence value

    difference in the cortico-subcortical electrophysiological coherence value between normal movement (control condition) and hypo- or hyperkinetic pathological movement

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Feb 2027, 36 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 36 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2024
First posted
Feb 5, 2024
StartActual
Feb 5, 2024
Primary completionEst.
Feb 5, 2027
CompletionEst.
Feb 5, 2027
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06241924
Responsible party
Sponsor
First posted
Feb 5, 2024
Start date
Feb 5, 2024
Primary completion
Feb 5, 2027 (estimated)
Completion
Feb 5, 2027 (estimated)
Last update
Jul 23, 2025

Study contacts

Jérôme AUPY, Docteur
Contact
jerome.aupy@u-bordeaux.fr
05 56 71 43 33
Jérôme AUPY, Docteur
principal investigator · University Hospital, Bordeaux

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion